Merck stock rises despite cautious 2026 outlook as patent losses loom
Merck shares climbed around 3.1% to $116.86 in midday trading Tuesday, despite the drugmaker warning its 2026 outlook would fall short of Wall Street expectations due to patent expirations on older drugs.